Paclitaxel/ Steroidal Compound

Technical Field

The present invention relates to a kind of paclitaxel steroid compound and its preparation, and the present invention also relates to the use of paclitaxel steroid compound, which belongs to the technical field of pharmaceutical preparations.

Background Art

Paclitaxel (paditaxel, Taxol) has a significant anti-tumor activity, which is widely used in clinical treatment of ovarian cancer, breast cancer, non-small cell lung cancer, head cancer and neck cancer, etc. Due to its practical insoluble in water (0.006μg/ml), the common injection Taxol® intended for the clinical treatment is prepared by dissolving 30mg of paclitaxel with 5ml of mixed solution containing Cremopher EL (polyoxyethylene castor oil)/ ethanol (50:50, V/V) . However, the solvent containing a large amount of Cremopher EL in formulation releases histamine in vivo, which can cause severe allergic reaction. In order to avoiding such side effects, the desensitization is to be done as followed before the clinical use: 10mg of dexamethasone is given by oral administration 12 hours before the treatment and 10mg of dexamethasone given again by oral administraion 6 hours before the treatment, 20mg of diphenhydramine i.m., 300mg of cimetidine or 50mg of ranitidine i.v. given 30~60 minutes before the treatment. In spite of precaution, 5% to 30% of patients has different degrees of allergic

Paclitaxel/ Steroidal Complex

Technical Field

The present invention relates to a kind of paclitaxel steroid compound and its preparation, and the present invention also relates to the use of paclitaxel steroid compound, which belongs to the technical field of pharmaceutical preparations.

Background Art

Paclitaxel (paditaxel, Taxol) has a significant anti-tumor activity, which is widely used in clinical treatment of ovarian cancer, breast cancer, non-small cell lung cancer, head cancer and neck cancer, etc. Due to its practical insoluble in water (0.006μg/ml), the common injection Taxol® intended for the clinical treatment is prepared by dissolving 30mg of paclitaxel with 5ml of mixed solution containing Cremopher EL (polyoxyethylene castor oil)/ ethanol (50:50, V/V) . However, the solvent containing a large amount of Cremopher EL in formulation releases histamine in vivo, which can cause severe allergic reaction. In order to avoiding such side effects, the desensitization is to be done as followed before the clinical use: 10mg of dexamethasone is given by oral administration 12 hours before the treatment and 10mg of dexamethasone given again by oral administraion 6 hours before the treatment, 20mg of diphenhydramine i.m., 300mg of cimetidine or 50mg of ranitidine i.v. given 30~60 minutes before the treatment. In spite of precaution, 5% to 30% of patients has different degrees of allergic